Updates on Clinical Trials in Systemic Lupus Erythematosus

Amir Sharabi*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review


Purpose of Review: Because of the complexity of systemic lupus erythematosus (SLE), different approaches are undertaken while investigating potential therapeutic compounds to treat the disease. The purpose of this review is to summarize the results from recent clinical trials, which investigated different compounds for treating SLE. Recent Findings: Targeting B cells and type I interferons constitutes the major focus in recent clinical trials. The potential for therapeutic effects of small molecule inhibition such as JAK, Tyk, and Btk is now being investigated for treating SLE. The immunoregulation of T cell activation in SLE is studied using low-dose IL-2 and CD40 ligand inhibition. There are clinical trials that study bispecific antibodies, with binding specificities for 2 different target molecules related to T- and B-cell activation or to different aspects of B cell activation. An approach of combination treatment is also being studied. Summary: Clinical trials are underway and new treatment compounds for SLE are being anticipated.

Original languageEnglish
Article number57
JournalCurrent Rheumatology Reports
Issue number7
StatePublished - Jul 2021


  • Clinical trials
  • Immunosuppression
  • Systemic lupus erythematosus (SLE)
  • Treatment


Dive into the research topics of 'Updates on Clinical Trials in Systemic Lupus Erythematosus'. Together they form a unique fingerprint.

Cite this